Last reviewed · How we verify
Acthrel (corticorelin ovine)
At a glance
| Generic name | corticorelin ovine |
|---|---|
| Sponsor | Ferring |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
| First approval | 1996 |
Approved indications
Common side effects
- Flushing of face, neck, and upper chest
- Dyspnea
- Tachycardia
- Hypotension
- Wheezing
- Urticaria
- Angioedema
- Chest compression or tightness
- Urge to take a deep breath
Serious adverse events
- Asystole requiring resuscitation
- Precipitous fall in blood pressure and pulse rate
- Loss of consciousness (absence-like)
- Grand mal epileptic seizure
Key clinical trials
- DDAVP for Pituitary Adenoma (NA)
- Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women (EARLY_PHASE1)
- Hormonal Mechanisms of Sleep Restriction - Axis Study (PHASE1)
- Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia (NA)
- Effects of Hormone Stimulation on Brain Scans for Cushing s Disease (EARLY_PHASE1)
- Gender and Neural Substrates of Stress and Craving
- Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures (PHASE1)
- Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acthrel CI brief — competitive landscape report
- Acthrel updates RSS · CI watch RSS
- Ferring portfolio CI